CTR1/SLC31A1抗体;CTR1/SLC31A1 Antibody—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

CTR1 (SLC31A1), a high-affinity copper transporter encoded by the SLC31A1 gene, is a transmembrane protein critical for cellular copper uptake. It facilitates copper influx into cells, maintaining essential copper homeostasis required for enzymatic functions (e.g., cytochrome c oxidase, superoxide dismutase) and signaling pathways. Dysregulation of CTR1 is linked to copper deficiency disorders, neurodegenerative diseases (e.g., Alzheimer’s, Menkes disease), and cancer, where altered copper metabolism influences tumor progression and chemotherapy resistance.

CTR1 antibodies are vital tools for detecting and quantifying CTR1 protein expression in research. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study tissue-specific distribution, subcellular localization, and expression changes under pathological conditions (e.g., cisplatin resistance in cancer). These antibodies help elucidate CTR1’s role in drug transport, as CTR1 also mediates the uptake of platinum-based chemotherapeutics.

Recent studies focus on CTR1’s structural characterization (e.g., three transmembrane domains, N-linked glycosylation sites) and regulatory mechanisms, including post-translational modifications and interactions with metal chaperones. Antibodies targeting specific epitopes aid in mapping functional domains and assessing CTR1 degradation under copper-limiting conditions. Understanding CTR1’s biology via these antibodies has therapeutic implications, such as optimizing chemotherapy efficacy or addressing copper-related metabolic disorders.